Vitamin D and COVID-19: where are we now?
- 27 December 2021
- journal article
- review article
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 135 (3) , 195-207
Abstract
The pandemic caused by the SARS-CoV-2 virus has triggered great interest in the search for the pathophysiological mechanisms of COVID-19 and its associated hyperinflammatory state. The presence of prognostic factors such as diabetes, cardiovascular disease, hypertension, obesity, and age influence the expression of the disease’s clinical severity. Other elements, such as 25-hydroxyvitamin D (25(OH)D3) concentrations, are currently being studied. Various studies, mostly observational, have sought to demonstrate whether there is truly a relationship between 25(OH)D3 levels and the acquisition and/or severity of the disease. The objective of this study was to carry out a review of the current data that associate vitamin D status with the acquisition, evolution, and/or severity of infection by the SARS-CoV-2 virus and to assess whether prevention through vitamin D supplementation can prevent infection and/or improve the evolution once acquired. Vitamin D system has an immunomodulatory function and plays a significant role in various bacterial and viral infections. The immune function of vitamin D is explained in part by the presence of its receptor (VDR) and its activating enzyme 25-hydroxyvitamin D-1alpha-hydroxylase (CYP27B1) in immune cells. The vitamin D, VDR, and Retinoid X Receptor complex allows the transcription of genes with antimicrobial activities, such as cathelicidins and defensins. COVID-19 characteristically presents a marked hyperimmune state, with the release of proinflammatory cytokines such as IL-6, TNF-α, and IL-1β. Thus, there are biological factors linking vitamin D to the cytokine storm, which can herald some of the most severe consequences of COVID-19, such as acute respiratory distress syndrome. Hypovitaminosis D is widespread worldwide, so the prevention of COVID-19 through vitamin D supplementation is being considered as a possible therapeutic strategy easy to implement. However, more-quality studies and well-designed randomized clinical trials are needed to address this relevant question.Keywords
Funding Information
- Institute of Health Carlos III (PI18-00803 and PI18-01235)
- European Regional Development Fund (FEDER) and Junta de Andalucía (PI-0268-2019)
- Junta de Andalucía and Institute of Health Carlos III (RH-0141-2020; CD20/00022)
This publication has 124 references indexed in Scilit:
- Vitamin D and Immune FunctionNutrients, 2013
- The Nonskeletal Effects of Vitamin D: An Endocrine Society Scientific StatementEndocrine Reviews, 2012
- Vitamin D3: a helpful immuno-modulatorImmunology, 2011
- T Cell Responses Are Required for Protection from Clinical Disease and for Virus Clearance in Severe Acute Respiratory Syndrome Coronavirus-Infected MiceJournal of Virology, 2010
- Vitamin D-Binding Protein Directs Monocyte Responses to 25-Hydroxy- and 1,25-Dihydroxyvitamin DThe Journal of Clinical Endocrinology & Metabolism, 2010
- Type I Interferons Regulate Cytolytic Activity of Memory CD8+ T Cells in the Lung Airways during Respiratory Virus ChallengeImmunity, 2010
- The Vitamin D Receptor: New Paradigms for the Regulation of Gene Expression by 1,25-Dihydroxyvitamin D3Endocrinology and Metabolism Clinics of North America, 2010
- Vitamin D DeficiencyNew England Journal of Medicine, 2007
- Vitamin D receptor-mediated suppression of RelB in antigen presenting cells: A paradigm for ligand-augmented negative transcriptional regulationArchives of Biochemistry and Biophysics, 2007
- Epidemic influenza and vitamin DEpidemiology and Infection, 2006